New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
11:37 EDTPSTI, LH, CYTX, LLY, NBS, ATHX, ACTC, FLDM, OVSC, STEM, PFEGenetics Policy Institute to host a summit
World Stem Cell Summit is being held in West Palm Beach, Florida on December 3-5 with webcasted presentations to begin on December 3 at 8 am. Webcast Link
News For LLY;PFE;ACTC;CYTX;STEM;ATHX;LH;OVSC;NBS;PSTI;FLDM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
January 22, 2015
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
07:15 EDTATHXAthersys announces GBP 2M grant to support Phase 2a clinical study of MultiStem
Subscribe for More Information
January 21, 2015
12:30 EDTPFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
16:25 EDTCYTXCytori says STAR trial will begin enrolling in 2015
Subscribe for More Information
08:40 EDTCYTXCytori Therapeutics price target raised to $6 from $3.50 at Roth Capital
Roth Capital increased its price target on Cytori after the company received final FDA approval for a clinical trial of its treatment for scleroderma., and the firm attended an event hosted by the company with a scleroderma expert. Roth says that the expert highlighted the unmet medical need in scleroderma as well its significant morbidity and mortality. The firm expects the company's visibility to improve this year, and it keeps a Buy rating on the stock.
08:21 EDTLHLabCorp upgraded to Buy from Hold at Evercore ISI
Subscribe for More Information
07:53 EDTFLDMFluidigm upgraded to Outperform at Cowen
Subscribe for More Information
07:33 EDTNBSNeoStem receives drug manufacture license for Irvine, CA facility
NeoStem announced that the State of California's Department of Public Health, Food and Drug Branch has completed its review of NeoStem's manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.
06:36 EDTFLDMFluidigm upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
January 16, 2015
12:20 EDTCYTXCytori Therapeutics price target raised to $6 from $3.50 at Roth Capital
Roth Capital raised its price target for Cytori Therapeutics to $6 and keeps a Buy rating on the name. The stock is rating up 3% to 46c.
January 15, 2015
11:20 EDTLLY, PFEGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:59 EDTPFEAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
07:07 EDTLLYEli Lilly upgraded at Goldman
As previously reported, Goldman upgraded Eli Lilly to Neutral from Sell. The firm upgraded shares based on new product launches and pipeline assets, and cost reductions. Price target is $70.
06:44 EDTLLYEli Lilly upgraded to Neutral from Sell at Goldman
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use